The nation of Zimbabwe has rejected a major US health deal valued at $367m (£272m) over five years because of the United States' demand for confidential data.
This rejection was revealed after a government memo from December was leaked, indicating that President Emmerson Mnangagwa felt the agreement was "skewed".
An official spokesperson later explained that the United States was requesting biological samples for scientific study and commercial gain but was not willing to share the benefits from any future vaccines.
"We must now begin the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated over $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further dialogue to find a deal suitable to both sides so the nation's critical HIV programme can be sustained.
Broader Background
Zimbabwe's decision follows a comparable case in Kenya, where a court blocked a similar deal with the US after legal challenges were raised about the security of Kenyans' medical information.
After returning to office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had managed assistance for the US government, but Trump argued its spending was "inefficient" and his administration was pursuing direct bilateral deals to enhance transparency and responsibility.
As per statements, Sixteen African countries have to date agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this cooperation might have yielded immense benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, with no corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our citizens if a new health crisis arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending frameworks previously set up through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This framework is designed to ensure that when a country provides its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage continued discussions with our American counterparts on how subsequent co-operation could be structured in a way that honours the sovereignty and interests of each country."
Health Experts Response
Medical experts expressed it recognised the official position, but urged that talks must proceed since much of the nation's Aids initiatives relied on foreign aid.
"In cases where technical issues arise, such as those relating to data governance or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
The situation highlights the complex challenges between receiving crucial international aid and safeguarding a country's data in an ever more interconnected world.